{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:01Z","timestamp":1791402301219,"version":"4.3.3"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Isavuconazole (ISA) is a newer triazole that has activity against most mold species and has been utilized for prophylaxis as well as treatment in patients with hematologic malignancies (HM) and hematopoietic stem cell transplant (HSCT). However, several studies have documented breakthrough invasive fungal infections (bIFIs). Thus, we conducted a systematic review and meta-analysis to investigate the incidence of bIFIs among patients receiving ISA prophylaxis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a systematic review and meta-analysis of the published literature using the concept of ISA, HSCT, and HM from 5 search engines. In patients with HSCT and HM, the pooled incidence of bIFI while undergoing ISA prophylaxis was calculated via the DerSimonian-Laird random effect model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The systematic review and meta-analysis included 35 and 19 studies, respectively. In total, 991 patients were identified as using ISA prophylaxis, and the majority had either acute myeloid leukemia or myelodysplastic syndrome (69.9%). The pooled incidence of proven\/probable bIFI was 7% (95% CI, 4%\u201312%, I2 = 55%). The most common pathogen was Aspergillus species (43.1%), followed by Candida (22.4%) and Mucorales (12.1%). In 19 studies, mortality rates were documented and ranged between 0% and 100%; the majority of which were &amp;gt;50%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with HM or HSCT, we found a high incidence of bIFI while undergoing ISA prophylaxis, with high mortality. Given the lack of randomized clinical trials evaluating ISA in this indication, its role in prophylaxis remains unclear.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf163","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:42:32Z","timestamp":1741966952000},"source":"Crossref","is-referenced-by-count":19,"title":["Incidence of Breakthrough Fungal Infections in Patients With Isavuconazole Prophylaxis: A Systematic Review and Meta-analysis"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0078-1268","authenticated-orcid":false,"given":"Keiko","family":"Ishida","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Toranomon Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6034-2786","authenticated-orcid":false,"given":"Mizuki","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Toranomon Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyoshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Toranomon Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3349-9296","authenticated-orcid":false,"given":"Hideki","family":"Araoka","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Toranomon Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1146-4746","authenticated-orcid":false,"given":"Akina","family":"Natori","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6744-3517","authenticated-orcid":false,"given":"John M","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Louis Calder Memorial Library, University of Miami Miller School of Medicine , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-5748","authenticated-orcid":false,"given":"Mohammed","family":"Raja","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, Miller School of Medicine, University of Miami , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4938-125X","authenticated-orcid":false,"given":"Yoichiro","family":"Natori","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, Miller School of Medicine, University of Miami , Miami, Florida ,","place":["USA"]},{"name":"Miami Transplant Institute, Jackson Health System , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"2025052712075412200_ofaf163-B1","doi-asserted-by":"crossref","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"New perspectives on antimicrobial agents: isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712075412200_ofaf163-B2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2025052712075412200_ofaf163-B3","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2025052712075412200_ofaf163-B4","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2025052712075412200_ofaf163-B5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025052712075412200_ofaf163-B6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025052712075412200_ofaf163-B7","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization","volume":"101","author":"Keirns","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2025052712075412200_ofaf163-B8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2025052712075412200_ofaf163-B9","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/mmy\/myab025","article-title":"Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"59","author":"Bogler","year":"2021","journal-title":"Med Mycol"},{"key":"2025052712075412200_ofaf163-B10","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2025052712075412200_ofaf163-B11","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712075412200_ofaf163-B12","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025052712075412200_ofaf163-B13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","article-title":"American Society of Transplantation and Cellular Therapy series, 2: management and prevention of aspergillosis in hematopoietic cell transplantation recipients","volume":"27","author":"Dadwal","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2025052712075412200_ofaf163-B14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jinf.2023.05.005","article-title":"Breakthrough invasive fungal infection among patients with haematologic malignancies: a national, prospective, and multicentre study","volume":"87","author":"Puerta-Alcalde","year":"2023","journal-title":"J Infect"},{"key":"2025052712075412200_ofaf163-B15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/cid\/ciae203","article-title":"Breakthrough invasive fungal infections in patients with high-risk hematological disorders receiving voriconazole and posaconazole prophylaxis: a systematic review","volume":"79","author":"Boutin","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025052712075412200_ofaf163-B16"},{"key":"2025052712075412200_ofaf163-B17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"2025052712075412200_ofaf163-B18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2025052712075412200_ofaf163-B19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5195\/jmla.2020.834","article-title":"Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial","volume":"108","author":"Clark","year":"2020","journal-title":"J Med Libr Assoc"},{"key":"2025052712075412200_ofaf163-B20","year":"2022"},{"key":"2025052712075412200_ofaf163-B21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) consensus group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025052712075412200_ofaf163-B22","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025052712075412200_ofaf163-B23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"key":"2025052712075412200_ofaf163-B24","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study","volume":"72","author":"Bose","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025052712075412200_ofaf163-B25","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712075412200_ofaf163-B26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025052712075412200_ofaf163-B27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11046-021-00583-9","article-title":"Clinical considerations of isavuconazole administration in high-risk hematological patients: a single-center 5-year experience","volume":"186","author":"Kronig","year":"2021","journal-title":"Mycopathologia"},{"key":"2025052712075412200_ofaf163-B28","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/cid\/ciy406","article-title":"Breakthrough fungal infections in patients with leukemia receiving isavuconazole","volume":"67","author":"Rausch","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025052712075412200_ofaf163-B29","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/cid\/ciac230","article-title":"Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies","volume":"75","author":"Rausch","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025052712075412200_ofaf163-B30","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv"},{"key":"2025052712075412200_ofaf163-B31","doi-asserted-by":"crossref","first-page":"S364","DOI":"10.1016\/S2666-6367(21)00466-8","article-title":"Comparing outcomes of different anti-fungal therapies as invasive fungal infection prophylaxis in allogeneic hematopoietic stem cell transplant recipients","volume":"27","author":"Chen","year":"2021","journal-title":"Cell Ther Transplant"},{"key":"2025052712075412200_ofaf163-B32","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2019-127120","article-title":"Isavuconazole prophylaxis during early phases of allogeneic HSC transplantation is not associated to an increase need of cyclosporin\u2014a dose modification","volume":"134","author":"Cupri","year":"2019","journal-title":"Blood"},{"key":"2025052712075412200_ofaf163-B33","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1093\/ofid\/ofy210.426","article-title":"Breakthrough invasive fungal infections in adult hematologic malignancy patients receiving isavuconazole prophylaxis","volume":"5","author":"DeVoe","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2025052712075412200_ofaf163-B34","volume-title":"Isavuconazole in allogeneic stem cell transplantation: a real-life report from the Spanish Group of Transplant and Cellular Therapy (GETH)","author":"Oarbeascoa","year":"2020"},{"key":"2025052712075412200_ofaf163-B35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-137637","article-title":"Phase 1 study of escalating doses of ibrutinib and temozolomide, etoposide, liposomal doxorubicin, dexamethasone, rituximab (TEDDI-R) with isavuconazole for relapsed and refractory primary CNS lymphoma","volume":"136","author":"Roschewski","year":"2020","journal-title":"Blood"},{"key":"2025052712075412200_ofaf163-B36","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1093\/ofid\/ofaa439.932","article-title":"Breakthrough invasive fungal infections with isavuconazonium sulfate versus voriconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia (AML) who received induction chemotherapy","volume":"7","author":"Singam","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025052712075412200_ofaf163-B37","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1182\/blood-2022-170143","article-title":"Ibrutinib alone or in combination with R-CHOP chemoimmunotherapy in relapsed or refractory primary central nervous system lymphoma (rrPCNSL): a \u00abreal-life\u00bb study","volume":"140","author":"Calimeri","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025052712075412200_ofaf163-B38","doi-asserted-by":"crossref","first-page":"e14162","DOI":"10.1111\/tid.14162","article-title":"Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy and hematopoietic stem cell transplant patients","volume":"25","author":"Khatri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2025052712075412200_ofaf163-B39","doi-asserted-by":"crossref","first-page":"1033.e1","DOI":"10.1016\/j.jtct.2024.06.009","article-title":"Real-world experience with isavuconazole in allogeneic stem cell transplantation in Spain","volume":"30","author":"Kwon","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025052712075412200_ofaf163-B40","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1182\/blood-2023-177994","article-title":"Phase 2 response-adapted study of ibrutinib with temozolomide, etoposide, liposomal doxorubicin, dexamethasone, and rituximab (TEDDI-R) for secondary CNS lymphoma","volume":"142","author":"Simard","year":"2023","journal-title":"Blood"},{"key":"2025052712075412200_ofaf163-B41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/10781552231175825","article-title":"Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia","volume":"30","author":"White","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"2025052712075412200_ofaf163-B42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/jof7030217","article-title":"Breakthrough mucormycosis developing on Mucorales-active antifungals portrays a poor prognosis in patients with hematologic cancer","volume":"7","author":"Axell-House","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2025052712075412200_ofaf163-B43","doi-asserted-by":"crossref","first-page":"e0220621","DOI":"10.1128\/aac.02206-21","article-title":"Successful treatment of disseminated disease due to highly resistant Aspergillus calidoustus with a novel antifungal therapy","volume":"66","author":"Camargo","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712075412200_ofaf163-B44","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2025052712075412200_ofaf163-B45","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/cid\/ciy260","article-title":"Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: what is happening in the real-world setting?","volume":"67","author":"Fung","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025052712075412200_ofaf163-B46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/ijd.14943","article-title":"Tender subcubcutaneous plaques in a patient with acute myeloid leukemia","volume":"60","author":"Olamiju","year":"2021","journal-title":"Int J Dermatol"},{"key":"2025052712075412200_ofaf163-B47","doi-asserted-by":"crossref","first-page":"A532","DOI":"10.1016\/j.chest.2020.08.504","article-title":"A case of fibrinous organizing pneumonia secondary to invasive pulmonary mucormycosis","volume":"158","author":"Su","year":"2020","journal-title":"Chest"},{"key":"2025052712075412200_ofaf163-B48","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1016\/S2666-6367(21)00453-X","article-title":"Invasive aspergillosis remains associated with high mortality in hematopoietic transplant recipients in the current era","volume":"27","author":"Suarez","year":"2021","journal-title":"Cell Ther Transplant"},{"key":"2025052712075412200_ofaf163-B49","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MPH.0000000000002812","article-title":"Characterization of the use and efficacy of isavuconazonium sulfate in a pediatric oncology and stem cell transplant population: a single institution retrospective review","volume":"46","author":"Kunvarjee","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"key":"2025052712075412200_ofaf163-B50","first-page":"30","article-title":"Isavuconazole breakthrough disseminated Fusarium fujikuroi infection in a patient with allogeneic hematopoietic stem cell transplant: diagnostic and therapeutic challenges\u2014a case report","volume":"15","author":"Bosetti","year":"2023","journal-title":"Healthbook TIMES Oncol Hematol"},{"key":"2025052712075412200_ofaf163-B51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/jac\/dkad377","article-title":"Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes","volume":"79","author":"Matsuo","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025052712075412200_ofaf163-B52","doi-asserted-by":"crossref","first-page":"A1049","DOI":"10.1016\/j.chest.2023.07.768","article-title":"Pulmonary invasive mucormycosis following allogeneic stem cell transplantation","volume":"164","author":"Stempel","year":"2023","journal-title":"Chest"},{"key":"2025052712075412200_ofaf163-B53","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/cid\/ciad309","article-title":"Fosmanogepix therapy of disseminated fusarium infection","volume":"77","author":"Winston","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025052712075412200_ofaf163-B54","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3390\/jof9080805","article-title":"Potential implication of azole persistence in the treatment failure of two haematological patients infected with Aspergillus fumigatus","volume":"9","author":"Pel\u00e1ez-Garc\u00eda de la Rasilla","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2025052712075412200_ofaf163-B55","doi-asserted-by":"crossref","first-page":"1149298","DOI":"10.3389\/fonc.2023.1149298","article-title":"Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia","volume":"13","author":"Scium\u00e8","year":"2023","journal-title":"Front Oncol"},{"key":"2025052712075412200_ofaf163-B56","first-page":"964","article-title":"An uncommon case of fungal rhinosinusitis caused by the mold Exserohilum rostratum in a patient with relapsed acute myeloid leukemia: case report and review of the literature","volume":"53","author":"Thomas","year":"2023","journal-title":"Ann Clin Lab Sci"},{"key":"2025052712075412200_ofaf163-B57","doi-asserted-by":"crossref","first-page":"O952","DOI":"10.1111\/1469-0691.12688","article-title":"Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study","volume":"20","author":"Lerolle","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2025052712075412200_ofaf163-B58","doi-asserted-by":"crossref","first-page":"e00188-17","DOI":"10.1128\/AAC.00188-17","article-title":"Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses","volume":"61","author":"Tverdek","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712075412200_ofaf163-B59","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijantimicag.2017.03.021","article-title":"Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies","volume":"50","author":"Hachem","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2025052712075412200_ofaf163-B60","doi-asserted-by":"crossref","first-page":"e01034-17","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712075412200_ofaf163-B61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jac\/dkx354","article-title":"Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs","volume":"73","author":"Buil","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025052712075412200_ofaf163-B62","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/jof6040324","article-title":"Isavuconazole: mechanism of action, clinical efficacy, and resistance","volume":"6","author":"Ellsworth","year":"2020","journal-title":"J Fungi (Basel)"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf163\/62415420\/ofaf163.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf163\/62415420\/ofaf163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf163\/62415420\/ofaf163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:08:23Z","timestamp":1748362103000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf163\/8078659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf163","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,14]]},"article-number":"ofaf163"}}